Hunter Jackson

Dr. Jackson brings to Q Therapeutics more than 30 years' experience in the life science industry. He is Chairman and CEO of A6 Pharmaceuticals and serves as the Lead Independent Director for Q Therapeutics. Since April 2014, he has served as Executive Chairman of Navigen Pharmaceuticals, Inc., a company he led as President and Chief Executive Officer from 2006 until his appointment as Executive Chairman. From 1986 through 2006, Dr. Jackson was Chairman and Chief Executive Officer of NPS Pharmaceuticals, Inc., a company he co-founded to pioneer and deliver therapies that transform the lives of patients with rare diseases. In 2015, NPS was acquired by Shire Pharmaceuticals for $5.2 billion.

Dr. Jackson earned a Bachelor of Arts degree in American Literature from the University of Illinois, a Ph.D. in Psychobiology from Yale University, and completed postdoctoral work in the Neurosurgery Department at the University of Virginia Medical Center.